Our discovery alliances and technology infrastructures have only one goal, namely to do the best for our shared end products, and here starting with a shared learning process within our global academic and technological network is clearly the best way to improve end products for drug development.

It is our vision to keep you further updated with what is going on within Evotec, to tell you more about new integrated technologies, but also deepen the information about also historically strong core disease areas of Evotec. One of these historically very strong disease areas, with deep in-house expertise and knowledge, is CNS – neurodegenerative diseases. Neurodegenerative diseases are globally wide spread and surely represent one of the major burdens for the healthcare systems around the world. Our goal is, in collaboration with you, to create and develop new and more effective drugs in this field.

This second edition of our DDup (Drug Discovery Update) will guide you through our recently established alliance in Alzheimer’s Disease (AD) with Roche and will give you a closer look on our in-house AD drug discovery expertise.

Download the publication to learn more about our CHDI collaboration, Alzheimer's, ALS and Phenotypic screening, stem cell based assays, and more surrounding neurodegenerative diseases in this Drug Discovery Update #2.